Pharmacological interventions for treatment of sarcopenia: current status of drug development for sarcopenia

Cited 24 time in scopus
Metadata Downloads
Title
Pharmacological interventions for treatment of sarcopenia: current status of drug development for sarcopenia
Author(s)
Ju Yeon KwakKi-Sun Kwon
Bibliographic Citation
Annals of Geriatric Medicine and Research, vol. 23, no. 3, pp. 98-104
Publication Year
2019
Abstract
Sarcopenia, the loss of skeletal muscle mass and function with age, was first recognized as a disease in the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) (M62.84) and has recently attracted attention as aged populations increase. However, the diagnostic criteria for sarcopenia remain controversial and there are as yet no US Food and Drug Administration-approved medications for sarcopenia. Given that both intrinsic and extrinsic factors contribute to sarcopenia onset and development, understanding the mechanism of sarcopenia is important for the development of therapeutic strategies. In this review, we described a variety of drugs for sarcopenia under investigation, including myostatin/ActR2 signaling inhibitors, exercise mimetics, anabolic hormones, and natural compounds. However, the combination of non-drug therapies with exercise and nutritional supplements are also needed as more easily accessible intervention strategies against sarcopenia rather than pharmacological treatments alone. Many approaches to develop therapeutic methods to overcome sarcopenia may lead to healthy aging.
Keyword
AgingDiagnosisDrugSarcopeniaSkeletal muscle
ISSN
2508-4798
Publisher
Korea Soc-Assoc-Inst
DOI
http://dx.doi.org/10.4235/agmr.19.0028
Type
Article
Appears in Collections:
Division of Research on National Challenges > Aging Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.